Hiroshi Wada's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q3 2025
Question
Hiroshi Wada from SMBC Nikko Securities asked about the likelihood of Entyvio being included in the U.S. IRA price negotiations in 2028.
Answer
CEO Christophe Weber confirmed that Entyvio's inclusion in the IRA in 2028 is a possibility. He stated this potential outcome is the reason the company has maintained a peak sales forecast range of $7.5 billion to $9 billion for the product, as it accounts for this risk.